Edgewise Therapeutics
EWTX
85 hedge funds and large institutions have $392M invested in Edgewise Therapeutics in 2023 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 41 increasing their positions, 17 reducing their positions, and 18 closing their positions.
200% more call options, than puts
Call options by funds: $6K | Put options by funds: $2K
141% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 17
1.98% less ownership
Funds ownership: 109.82% → 107.85% (-2%)
11% less funds holding
Funds holding: 95 → 85 (-10)
27% less capital invested
Capital invested by funds: $539M → $392M (-$147M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
50% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$3.74M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
+$3.67M |
| 3 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$2M |
| 4 |
Viking Global Investors
Stamford,
Connecticut
|
+$1.47M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$692K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.49M |
| 2 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$5.52M |
| 3 |
Goldman Sachs
New York
|
-$5.48M |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$2.7M |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
-$1.07M |
EWTX Hedge Fund Activity: Q3 2023 in Review
85 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Edgewise Therapeutics (EWTX) for Q3 2023, worth a combined $392M — down 27% from $539M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of EWTX and 9 opened new positions — a net loss of 9 holders — while 17 trimmed existing stakes and 41 added.
The largest buyer was Baker Bros. Advisors, adding an estimated $3.74M. The largest seller was Fidelity Investments, cutting an estimated $6.49M.
- 85 institutional investors held Edgewise Therapeutics (EWTX) as of Q3 2023, down from 95 in Q2 2023.
- Funds reported $392M of Edgewise Therapeutics stock for Q3 2023, down 27% quarter-over-quarter.
- 9 funds opened new Edgewise Therapeutics positions in Q3 2023 and 18 closed out, a net change of -9 holders.
- The largest Edgewise Therapeutics buyer in Q3 2023 was Baker Bros. Advisors, an estimated $3.74M added.
- The largest Edgewise Therapeutics seller in Q3 2023 was Fidelity Investments, an estimated $6.49M sold.
Based on aggregated 13F filings for Q3 2023.